| Recruiting | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With A Metastatic Solid Tumor, Advanced Solid Tumor | Phase 1 | 2025-04-01 |
| Not Yet Recruiting | A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors Advanced or Metastatic Solid Tumors | Phase 1 | 2025-02-15 |
| Active Not Recruiting | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and Hepatocellular Carcinoma | Phase 2 | 2024-12-20 |
| Recruiting | A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer Recurrent | Phase 4 | 2024-11-01 |
| Terminated | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tum Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma | Phase 1 | 2023-04-26 |
| Recruiting | Study of CHS-114 in Participants With Advanced Solid Tumors Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma | Phase 1 | 2022-12-15 |
| Completed | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma Hepatocellular Carcinoma | Phase 2 | 2022-04-12 |
| Terminated | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resi Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | Phase 2 | 2022-01-17 |
| Unknown | An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca Febrile Neutropenia, Non-myeloid Malignancy | — | 2020-08-01 |
| Completed | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma | Phase 1 | 2020-04-22 |
| Completed | Study of SRF617 in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2020-03-16 |
| Completed | Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta Healthy | Phase 1 | 2016-02-01 |
| Completed | Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis Plaque Psoriasis | Phase 3 | 2015-08-01 |
| Completed | A Long Term Safety Extension Study (CHS-0214-05) Rheumatoid Arthritis, Plaque Psoriasis | Phase 3 | 2015-07-01 |
| Completed | Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous D Immunity, Humoral | Phase 1 | 2015-05-01 |
| Completed | Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With N Bioequivalence | Phase 1 | 2015-02-01 |
| Completed | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) Plaque Psoriasis | Phase 3 | 2014-06-16 |
| Completed | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA) Rheumatoid Arthritis | Phase 3 | 2014-05-01 |